This phase IV longitudinal interventional study conducted in Finland, the Netherlands and the UK is described in detail elsewhere (10 (link)). In summary, healthy children (7-10 y), adolescents (11-15y), young adults (20-34 y), and older adults (60-70 y) received Boostrix-IPV (GlaxoSmithKline (GSK), Wavre, Belgium), a three component pertussis vaccine (Tdap3-IPV), between October 2017 and January 2019. Children were all aP primed, adolescents were either aP or wP primed, young adults were all wP primed, and older adults were either wP primed or unvaccinated. B cell assays were performed on a subset of the total study samples given the resources needed to undertake the assay (total n= 268 out of 379). Samples were selected according to a prespecified sample plan based on participant ID. For the memory B cell analyses the samples were collected before vaccination (baseline), and at day 28 and 1 year post-vaccination. Figure 1 shows the number of participants per country, per age group, and per timepoint. Their characteristics are listed in Table 1. The trial was registered at the EU Clinical Trial database (EudraCT number 2016-003678-42).
Free full text: Click here